However, there remain a small subgroup of patients with levels of 10–45 ng/mL where advanced neoplasia will be missed, and for this reason, NHS England has proposed a clinical evaluation, offering CCE to individuals with FIT concentrations in the 10–99 ng Hb/mL range [76,77,78]. The gene discussed is GSTM1; the disease is neoplasm.